TFX

Business Context and Reporting Period

Company: Teleflex Incorporated
Filing Type: Form 10-K (Annual Report)
Period Ended: December 25, 2005
Business Overview: Teleflex is a diversified industrial company specializing in specialty-engineered products for commercial, medical, and aerospace industries. Operations span 24 countries, with 55% of revenues generated outside the United States. The company is organized into three segments: Commercial (47% of revenue), Medical (33%), and Aerospace (20%).

Key Financial Metrics

Segment Performance (Operating Profit):

• Commercial: $81.1 million (Declined 23% vs. 2004)
• Medical: $150.0 million (Increased 29% vs. 2004)
• Aerospace: $33.4 million (Turned profitable from a $10.5 million loss in 2004)

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 5% to $2.51 billion, driven by 5% core growth and 4% from acquisitions, partially offset by 3% from dispositions and 1% from reporting lag adjustments.
• Profitability Surge: Net income increased by $129.3 million (1,361% increase) primarily due to a 60% reduction in restructuring costs and a significant gain on the sale of the Sermatech business.
• Restructuring Costs: Restructuring charges dropped to $27.1 million in 2005 from $67.6 million in 2004. The company expects future cost savings from the program to range between $60 million and $80 million in 2006.
• Debt Reduction: Total debt decreased by approximately $157 million due to proceeds from business dispositions and improved operating cash flow.
• Discontinued Operations: The company completed the sale of several non-core businesses in 2005, including the automotive pedal systems business and Sermatech International, which are now reported as discontinued operations.

Guidance, Outlook, and Risks

Management Commentary & Outlook:
Management expects core revenue growth to continue through product development and market expansion. The restructuring program is substantially complete, with anticipated cost savings materializing in 2006. The company repatriated $304 million of foreign earnings in late 2005 under the American Jobs Creation Act, resulting in a net tax benefit.

Stock Repurchases:
The Board authorized a $140 million stock repurchase program in July 2005. As of year-end, $46.5 million had been utilized to repurchase 690,100 shares.

Key Risks:

• Cyclical Exposure: Significant exposure to cyclical industries (automotive, aerospace, marine) which may face economic downturns.
• Foreign Operations: 55% of revenues are from outside the U.S., exposing the company to currency fluctuations, trade protection measures, and political instability.
• Customer Concentration: Products are integrated into customers' products; demand changes or contract cancellations by major OEMs could materially impact revenue.
• Regulatory Environment: Subject to strict regulation by the FDA, FAA, and NHTSA, as well as environmental laws.

Investor Verification Checklist

• Discontinued Operations Impact: Verify the extent to which the 2005 net income improvement is driven by one-time gains from asset sales (Sermatech) versus sustainable operational improvements.
• Restructuring Completion: Confirm the timeline and actual realization of the projected $60-$80 million in cost savings for 2006.
• Medical Segment Growth: Assess the sustainability of the Medical segment's growth following the HudsonRCI acquisition and the impact of third-party reimbursement policies.
• Commercial Segment Margins: Investigate the causes of the 23% decline in Commercial operating profit, specifically regarding duplicate costs and the bankruptcy of an automotive supplier.
• Currency Hedging: Review the effectiveness of the currency hedging program given that 55% of revenues are international and the U.S. dollar strength/weakness impacts reported earnings.